QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • VistaGen Therapeutics, Inc. (VSTA) Positioned To Benefit From Multiple Monetization Options 0 comments
    May 2, 2013 2:32 PM | about stocks: VTGN

    Stem cell technology has traditionally been associated with therapeutic regeneration, using these basic building blocks of life to generate new cells that can replace damaged cells. Potential therapeutic applications run the gamut from the replacement of damaged nerve cells to the generation of new heart or liver tissue. However, VistaGen Therapeutics, which is in fact involved in researching and developing therapeutic applications, is best known for a totally different but no less important application of stem cell technology.

    Stem cells, in addition to therapeutic applications, can allow scientists to generate mature human cells right in the laboratory; cells that can then be used to efficiently screen drugs for possible toxicity without going through the time and expense involved in human clinical trials, and this is just what VistaGen is focused on doing. The company's proprietary Human Clinical Trials in a Test Tube stem cell based drug assay platform provides a major advantage to anyone involved in the extremely expensive and risky process of new drug development.

    In particular, VistaGen plans to use the technology itself to build a pipeline of drug rescue variants, drugs that have important therapeutic potential but have been shelved due to heart or liver toxicity issues. VistaGen is convinced that it can rescue some of these drugs, using their unique in-lab testing system to economically tweak them, maintaining their demonstrated efficacy while removing their toxicity. VistaGen can then enjoy significant economic participation rights as the new drug is taken to market.

    Clearly there are also other rich options the company may soon find itself considering. A powerful technology such as this could result in billions of dollars saved, by helping to avoid the massive costs involved in going to market with a fatally flawed new drug, and such a tool, once finalized, could carry huge licensing potential. In addition, VistaGen could easily become a takeover target, as large pharmaceutical companies look for quick ways to fill profit gaps left by expiring patents.

    For additional information, visit VistaGen.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: VTGN
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.